bretylium (Bretylol) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Bretylium (bretylium tosylate) is an antifibrillatory and antiarrhythmic agent. Bretylium is abromobenzyl quaternary ammonium compound which selectively accumulates in sympathetic ganglia and their postganglionic adrenergic neurons where it inhibits norepinephrine release by depressing adrenergic nerve terminal excitability. The drug has a direct positive inotropic effect on the myocardium and blocking effect on postganglionic sympathetic nerve transmission. The drug is poorly absorbed orally, requiring either i.m. or i.v. administration.   NCATS

Chemistry

  • SMILES: CC[N+](C)(C)Cc1ccccc1Br
  • InChIKey: AAQOQKQBGPPFNS-UHFFFAOYSA-N
  • Mol. Mass: 243.17
  • ALogP: 3.05
  • ChEMBL Molecules:
    bretylium  
    bretylium tosylate  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Alternative names

(2-bromobenzyl)ethyldimethylaminium | 2-bromo-n-ethyl-n,n-dimethylbenzenemethanaminium | asl-603 | brethyllium | bretylan | bretylate | bretylium | bretylium bromide | bretylium chloride | bretylium iodide | bretylium tosilate | bretylium tosylate | bretylol | n-ethyl-n,n-dimethyl-2-bromobenzenemethanaminium

Organizations (16)

Research & Development (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (15)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (3)

Approved Indications (2)


 

Arrhythmias, Cardiac

Ventricular Fibrillation

Experimental Indications - Clinical Trial Phases 1-4 (1)


 

Healthy Volunteers (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 1
  • # of Trial Organizations: 1

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue